Discogen para el dolor lumbar
Estudio piloto de viabilidad doble ciego del dispositivo Discogen para aliviar el dolor discogénico de espalda o pierna radicular
This study will be a double-blinded, two-arm, prospective, randomized controlled pilot feasibility study in 40 evaluable subjects (20 in each arm) at one study site within the United States. Subjects in Arm 1 will receive unilateral Discogen treatment; subjects in Arm 2 will receive unilateral sham treatment (control). Treatment in both arms can include medications, e.g. NSAIDs or muscle relaxants for axial or radicular pain.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This study will be a double-blinded, two-arm, prospective, randomized controlled pilot feasibility study in 40 evaluable subjects (20 in each arm) at one study site within the United States. Subjects in Arm 1 will receive unilateral Discogen treatment; subjects in Arm 2 will receive unilateral sham treatment (control). Treatment in both arms can include medications, e.g. NSAIDs or muscle relaxants for axial or radicular pain. This study will enroll 40 evaluable subjects and follow them for 60 days.
-
Investigate the safety and feasibility of the Discogen device to alleviate back/radicular leg pain
-
Assess the mean reduction in back and radicular leg pain following Discogen treatment.
-
Primary Safety - collection of all adverse events, including any device- or procedure-related adverse events
-
Primary Effectiveness -percent change from baseline for Numerical Pain Scale (NPS) radicular leg pain at 30 and 60 days. The scale ranges from 0(No pain) to 10 (Severe pain).
-
Secondary Effectiveness:
- Change from baseline in Oswestry Disability Index at 30 and 60 days. The Index ranges from 0-20% (minimal disability), 21-40% (moderate disability), 41-60% (severe disability), 61-80% (crippled), to 81-100% (bed bound).
- Percent change from baseline NPS back pain at 30 and 60 days
-
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Michael Spinner, MS
- Número de teléfono: 212-305-9416
- Correo electrónico: ms6431@cumc.columbia.edu
Copia de seguridad de contactos de estudio
- Nombre: Clark Smith, MD, PhD
- Número de teléfono: 212-305-2134
- Correo electrónico: cs3028@cumc.columbia.edu
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- Columbia University Irving Medical Center
-
Contacto:
- Michael Spinner
- Número de teléfono: 5164594518
- Correo electrónico: ms6431@cumc.columbia.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
The subject may be included in the study if the following conditions are met:
- Adult (> 21 y.o.) males and females legally able and willing to participate and provide consent in the study and attend follow-up visits
- Able and willing to complete study forms and communicate with the investigator
- Presenting with unilateral radicular leg pain with or without axial back pain of >1 month duration
- No epidural injections at treatment site within the last three months
- Leg NPS pain score of 4 - 9 in the last month (on a scale of 0 to 10)
- Clinical presentation of sensory radiculopathy referable to single-level disc disease/herniation at L3-4, L4-5 or L5-S1
- MRI lumbar spine negative for extruded disc herniation, tumor, or bleeding, but positive for disc disease/herniation at L3-4, L4-5 or L5-S1 with mild to moderate foraminal or spinal stenosis (less than 50%).
Exclusion Criteria:
- Pregnant or breastfeeding patient
- Younger than 21 or older than 75 years
- Presenting with motor deficits
- Presenting with a baseline Oswestry Disability Index ≥ 41% (severe disability or worse)
- Presence of metal hardware within the lumbosacral spine
- History of spine surgery at the level of treatment.
- Lumbar spine pathology that may increase procedural risk and/or influence symptoms and/or generate unrelated adverse events (per the discretion of the study PI)
- Severe lumbar central canal stenosis (greater than 50%)
- Severe lumbar foraminal stenosis (greater than 50%)
- Severe herniated lumbar disc 4(Grade 2 and above)
- Lumbar instability on flexion/extension plain films, greater the Grade 1 spondylolisthesis
- Unable to understand and complete research questionnaires
- Any severe medical condition preventing the patient from safely and effectively being treated in the study or reporting study outcomes.
- BMI greater than 30
- Implanted spinal stimulators
- Epidural injections at treatment site within the last three months
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment Group
Study subjects in the treatment group (Arm 1) will receive 3 daily Discogen treatments unilaterally within a one week (M-M) period, each lasting 25 minutes. |
The device is a customized Low Intensity Pulsed Ultrasound (LIPUS) transducer system and power source. The transducer is biocompatible for skin contact. The system is capable of calibration to desired treatment parameters. The study subject will be placed in the prone position with all appropriate pressure points padded on the exam table. For the first treatment, fluoroscopic imaging (and/or ultrasonic guidance) will be used to guide the placement of the transducer over the anatomic target, unilateral at the L3-4, L4-5 or L5-S1 levels. The skin of the study subject's back will be marked with non-washable marking pen to indicate the site for placing the transducer during the first treatment. The subsequent treatment (second and third) can be done without using ultrasound guidance. The transducer will be placed on the marked site during the second and third treatment. The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power ge |
|
Comparador falso: Sham Control Group
Subjects in the sham control arm (Arm 2) will receive 3 daily non-powered treatments unilaterally within a one week (M-M) period, each lasting 25 minutes |
The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power generator will not be turned on for the sham treatment, but the wave generator will be displayed. All study subjects will receive a total of three daily Discogen treatments over the span of a single M-M work week |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Primary Effectiveness
Periodo de tiempo: 30 and 60 days.
|
Percent change from baseline for Numerical Pain Scale (NPS) radicular leg pain at 30 and 60 days. The NPS is a patient-reported assessment of pain intensity, ranging from 0 (No pain) to 10 (Severe pain). |
30 and 60 days.
|
|
Primary Safety
Periodo de tiempo: 60 days
|
Collection of all adverse events, including any device or procedure-related adverse events. |
60 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in Oswestry Disability Index
Periodo de tiempo: 30 and 60 days.
|
The Oswestry Disability Index is a patient-reported assessment of level of function (disability) in those living with low back pain. The Index ranges from 0-20% (minimal disability), 21-40% (moderate disability), 41-60% (severe disability), 61-80% (crippled), to 81-100% (bed bound). |
30 and 60 days.
|
|
Numerical Pain Scale (NPS)
Periodo de tiempo: 30 and 60 days.
|
Percent change from baseline NPS back pain. The scale ranges from 0 (No pain) to 10 (Severe pain). |
30 and 60 days.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Clark Smith, MD, PhD, Columbia University
Publicaciones y enlaces útiles
Publicaciones Generales
- Su ZH, Liu J, Yang MS, Chen ZY, You K, Shen J, Huang CJ, Zhao QH, Liu EQ, Zhao L, Feng QJ, Pang SM, Li SL, Lu H. Automatic Grading of Disc Herniation, Central Canal Stenosis and Nerve Roots Compression in Lumbar Magnetic Resonance Image Diagnosis. Front Endocrinol (Lausanne). 2022 Jun 6;13:890371. doi: 10.3389/fendo.2022.890371. eCollection 2022.
- PASS 2021 Power Analysis and Sample Size Software (2021). NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass.
- Fiore P, Panza F, Cassatella G, Russo A, Frisardi V, Solfrizzi V, Ranieri M, Di Teo L, Santamato A. Short-term effects of high-intensity laser therapy versus ultrasound therapy in the treatment of low back pain: a randomized controlled trial. Eur J Phys Rehabil Med. 2011 Sep;47(3):367-73. Epub 2011 Jun 8.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- AAAU8219
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .